Literature DB >> 20358197

Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study.

Mona Mustafa1, Torsten Kuwert, Kathrin Weber, Peter Knesewitsch, Thomas Negele, Alexander Haug, Rainer Linke, Peter Bartenstein, Daniela Schmidt.   

Abstract

PURPOSE: Hybrid imaging combining single photon emission computed tomography (SPECT) with (131)I and X-ray computed tomography (CT) performed at radioablation (RA) for thyroid carcinoma more accurately detects regional lymph node metastases (LNM) than does planar imaging. In this bicentric prospective study we used hybrid imaging in conjunction with histopathological examination to measure LNM frequency in a consecutive group of patients referred for RA due to stage T1 papillary thyroid carcinoma (PTC).
METHODS: At the Departments of Nuclear Medicine of the Ludwig Maximilian University of Munich and the Friedrich Alexander University of Erlangen-Nuremberg SPECT/spiral CT is routinely performed in all PTC subjects at the time of RA. Screening of our SPECT/CT databases for PTC patients with T1 histology produced 98 patients from Munich and 53 patients from Erlangen, including 96 of 151 patients with microcarcinoma. In 69 patients of the entire group, cervical lymph node dissection had been performed, whereas nodal staging in the remaining 82 subjects was based on SPECT/CT.
RESULTS: LNM incidence in the whole group was 26% [95% confidence interval (CI): 20-33%] versus 22% (95% CI: 15-31%) in the microcarcinoma subgroup. SPECT/CT was more accurate in 24.5% of our patients than planar imaging with regard to nodal staging.
CONCLUSION: LNM occurs in one quarter of all patients with T1 PTC, and also in the subset with microcarcinoma. Performing (131)I SPECT/CT, either with therapeutic or diagnostic radioactivities, directly after thyroidectomy should provide more accurate staging of T1 PTC, thus facilitating optimal therapeutic management.

Entities:  

Mesh:

Year:  2010        PMID: 20358197     DOI: 10.1007/s00259-010-1408-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  9 in total

1.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

2.  Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests.

Authors:  M Dietlein; D Moka; K Scheidhauer; M Schmidt; P Theissen; E Voth; W Eschner; H Schicha
Journal:  Nucl Med Commun       Date:  2000-11       Impact factor: 1.690

3.  Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.

Authors:  Sin-Ming Chow; Stephen C K Law; John K C Chan; Siu-Kie Au; Stephen Yau; Wai-Hon Lau
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

4.  Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases.

Authors:  Gabriella Pellegriti; Claudia Scollo; Gabriella Lumera; Concetto Regalbuto; Riccardo Vigneri; Antonino Belfiore
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

5.  Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer.

Authors:  Nicolas Aide; Natacha Heutte; Jean-Pierre Rame; Elise Rousseau; Cédric Loiseau; Michel Henry-Amar; Stéphane Bardet
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

6.  Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation.

Authors:  Daniela Schmidt; Attila Szikszai; Rainer Linke; Werner Bautz; Torsten Kuwert
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

Review 7.  Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma.

Authors:  K K Wong; N Zarzhevsky; J M Cahill; K A Frey; A M Avram
Journal:  Br J Radiol       Date:  2009-05-11       Impact factor: 3.039

8.  Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?

Authors:  Nimmi Arora; Harma K Turbendian; Meredith A Kato; Tracy A Moo; Rasa Zarnegar; Thomas J Fahey
Journal:  Thyroid       Date:  2009-05       Impact factor: 6.568

9.  Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.

Authors:  Stéphane Bonnet; Dana Hartl; Sophie Leboulleux; Eric Baudin; Jean D Lumbroso; Abir Al Ghuzlan; Linda Chami; Martin Schlumberger; Jean Paul Travagli
Journal:  J Clin Endocrinol Metab       Date:  2008-12-30       Impact factor: 5.958

  9 in total
  14 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 3.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

4.  [SPECT/CT for staging and treatment monitoring in oncology. Applications in differentiated thyroid cancer and liver tumors].

Authors:  K Weber; F Berger; M Mustafa; M F Reiser; P Bartenstein; A Haug
Journal:  Radiologe       Date:  2012-07       Impact factor: 0.635

5.  Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Özdemir; Neslihan Çuhacı; Hüsniye Başer; Cevdet Aydın; Aylin Kılıç Yazgan; Reyhan Ersoy; Bekir Çakır
Journal:  Endocrine       Date:  2016-04-18       Impact factor: 3.633

Review 6.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08

7.  Clinical Utility of SPECT/CT Imaging Post-Radioiodine Therapy: Does It Enhance Patient Management in Thyroid Cancer?

Authors:  Fahim U Hassan; Hosahalli K Mohan
Journal:  Eur Thyroid J       Date:  2015-07-31

8.  I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan.

Authors:  Julia V Malamitsi; John T Koutsikos; Stamatia I Giourgouli; Sophia F Zachaki; Theodoros A Pipikos; Fani J Vlachou; Vassilios K Prassopoulos
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

9.  Number of Foci of Functioning Thyroid Tissue Remaining after Thyroidectomy for Differentiated Thyroid Cancer: Institutional Experience.

Authors:  Kanchan Kulkarni; Gauri Khorjekar; Mihriye Mete; Douglas Van Nostrand
Journal:  World J Nucl Med       Date:  2017 Apr-Jun

10.  A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma.

Authors:  Zhou-Ci Zheng; Qing-Xuan Wang; Wei Zhang; Xiao-Hua Zhang; Du-Ping Huang
Journal:  Onco Targets Ther       Date:  2018-01-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.